表紙
市場調查報告書

流感A(H7N9)病毒感染疾病:開發中產品分析

Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 410980
出版日期 內容資訊 英文 127 Pages
訂單完成後即時交付
價格
Back to Top
流感A(H7N9)病毒感染疾病:開發中產品分析 Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 127 Pages
簡介

禽流感A (H7N9) 是亞型流感病毒,這個感染疾病在人和鳥類身上均可能出現。人類如暴露在感染的家禽或被污染的環境便容易感染。症狀有發燒,有痰的咳嗽,頭痛,肌肉酸痛和一般不適。治療包括抗病毒藥物等。

本報告提供流感A(H7N9)病毒感染疾病的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

流感A(H7N9)病毒感染疾病 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關研究中的產品

開發治療藥的企業

  • EpiVax Inc
  • Fab'entech
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Medigen Vaccine Biologics Corp
  • NanoViricides Inc
  • Visterra Inc
  • Vivaldi Biosciences Inc

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AT-501
  • FBF-002
  • GSK-3206640A
  • GSK-3206641A
  • 流感 毒株A/H7N9 (單價) 疫苗
  • 流感 毒株A/H7N9 疫苗
  • 流感病毒A感染疾病用抑制血凝素單株抗體
  • NVINF-1
  • NVINF-2
  • 流感病毒A感染疾病用唾液酸受體標的組換蛋白
  • VIS-410

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11675IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2019, provides an overview of the Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline landscape.

Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia and general malaise. Treatment includes antiviral drugs

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 6, 16 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 4 and 3 molecules, respectively.

Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Influenza A Virus, H7N9 Subtype Infections - Overview
    • Influenza A Virus, H7N9 Subtype Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Influenza A Virus, H7N9 Subtype Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Influenza A Virus, H7N9 Subtype Infections - Companies Involved in Therapeutics Development
    • AIM ImmunoTech Inc
    • AusBio Ltd
    • Beijing Minhai Biotechnology Co Ltd
    • Cocrystal Pharma Inc
    • Codagenix Inc
    • CSL Ltd
    • EpiVax Inc
    • Genentech Inc
    • Greffex Inc
    • Hualan Biological Bacterin Co Ltd
    • Inovio Pharmaceuticals Inc
    • Medicago Inc
    • Medigen Vaccine Biologics Corp
    • Moderna Therapeutics Inc
    • NanoViricides Inc
    • New Amsterdam Sciences Inc
    • Ology Bioservices Inc
    • Pneumagen Ltd
    • Sanofi Pasteur SA
    • Seqirus Ltd
    • Shanghai Institute of Biological Products Co Ltd
    • Shionogi & Co Ltd
    • Virion Biotherapeutics
    • Visterra Inc
    • Vivaldi Biosciences Inc
  • Influenza A Virus, H7N9 Subtype Infections - Drug Profiles
  • Influenza A Virus, H7N9 Subtype Infections - Dormant Projects
  • Influenza A Virus, H7N9 Subtype Infections - Discontinued Products
  • Influenza A Virus, H7N9 Subtype Infections - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by AIM ImmunoTech Inc, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by AusBio Ltd, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Codagenix Inc, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by CSL Ltd, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by EpiVax Inc, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Genentech Inc, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Greffex Inc, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Hualan Biological Bacterin Co Ltd, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medicago Inc, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medigen Vaccine Biologics Corp, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Moderna Therapeutics Inc, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by NanoViricides Inc, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by New Amsterdam Sciences Inc, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Ology Bioservices Inc, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Pneumagen Ltd, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Sanofi Pasteur SA, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Seqirus Ltd, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Shanghai Institute of Biological Products Co Ltd, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Shionogi & Co Ltd, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Virion Biotherapeutics, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Visterra Inc, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Vivaldi Biosciences Inc, H2 2019
  • Influenza A Virus, H7N9 Subtype Infections - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top